Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) traded down 5.5% during mid-day trading on Friday . The company traded as low as $24.99 and last traded at $24.99. 387,690 shares were traded during trading, a decline of 56% from the average session volume of 885,998 shares. The stock had previously closed at $26.45.
Wall Street Analyst Weigh In
CLDX has been the subject of several research analyst reports. Citigroup started coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $70.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a report on Monday, September 30th. They set a "neutral" rating and a $45.00 price target on the stock. Wolfe Research lowered Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Finally, Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $62.25.
Get Our Latest Stock Analysis on Celldex Therapeutics
Celldex Therapeutics Trading Down 3.9 %
The firm has a 50-day simple moving average of $27.28 and a two-hundred day simple moving average of $33.65. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -9.89 and a beta of 1.57.
Insiders Place Their Bets
In related news, CEO Anthony S. Marucci purchased 11,500 shares of Celldex Therapeutics stock in a transaction on Monday, November 11th. The stock was bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.80% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CLDX. KBC Group NV grew its position in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics during the 2nd quarter valued at approximately $76,000. Los Angeles Capital Management LLC grew its holdings in Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 638 shares during the last quarter. Quest Partners LLC grew its holdings in Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 6,879 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock worth $291,000 after buying an additional 1,504 shares during the period.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Articles
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
